Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer

Immunity. 2016 Jun 21;44(6):1248-50. doi: 10.1016/j.immuni.2016.06.010.


Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. In this issue of Immunity, June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes Tn and sialyl-Tn on cancer-associated MUC-1.

Publication types

  • Comment

MeSH terms

  • Glycosylation
  • Humans
  • Neoplasms / immunology*
  • T-Lymphocytes / immunology*